2023 World Conference on Lung Cancer (Posters)-EP09.05. Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease

EP09.05. Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed changes in pulmonary function following single and multi-fraction stereotactic body radiotherapy (SBRT) for pulmonary oligometastatic disease. The SAFRON II trial compared the efficacy and toxicity of single fraction (SF) SBRT and multi-fraction (MF) SBRT in patients with 1-3 pulmonary oligometastases. The analysis assessed differences in pulmonary function tests (PFTs) between the two treatment arms and the relationship between changes in PFTs and the number and volume of targets treated.<br /><br />The study included 90 patients, with 44 randomized to the SF arm and 43 to the MF arm. There were no differences in absolute or relative PFT measures of FEV1 or DLCO between the two arms. At 12 months, the overall changes in absolute DLCO, relative DLCO, and absolute FEV1 from baseline were -1.7%, -5.5%, and -0.17, respectively. <br /><br />In patients with multiple pulmonary targets, there was a significant association observed between a reduction in absolute FEV1 at 6 and 12 months with an increased number of targets treated. A reduction in FEV1 was also seen with an increase in the volume of the planning target volume (PTV) at 12 months. However, this association was not observed with DLCO.<br /><br />The study concluded that there were no differences in PFT decline between SF and MF SBRT. It was found that a decline in absolute FEV1 at 6 and 12 months was associated with an increased number of targets and a higher PTV volume.<br /><br />This study provides valuable insights into the pulmonary function changes following SBRT for pulmonary oligometastatic disease and highlights the importance of considering the number and volume of targets treated in relation to FEV1 decline.

Asset Subtitle

Nicholas Bucknell

Meta Tag

Speaker Nicholas Bucknell

Topic Metastatic NSCLC: Local Therapies - Toxicity of Local Therapies

Keywords

pulmonary function

SBRT

pulmonary oligometastatic disease

SAFRON II trial

single fraction

multi-fraction

FEV1

DLCO

number of targets treated

PTV volume